AstraZeneca PLC (AZN)
76.33
+0.55
(+0.73%)
USD |
NASDAQ |
May 07, 16:00
76.33
0.00 (0.00%)
After-Hours: 17:07
AstraZeneca SG&A Expense (Quarterly): 4.63B for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 4.63B |
December 31, 2023 | 3.983B |
September 30, 2023 | 4.929B |
June 30, 2023 | 5.117B |
March 31, 2023 | 4.193B |
December 31, 2022 | 3.806B |
September 30, 2022 | 4.403B |
June 30, 2022 | 4.81B |
March 31, 2022 | 4.965B |
December 31, 2021 | 5.151B |
September 30, 2021 | 4.21B |
June 30, 2021 | 3.201B |
March 31, 2021 | 3.028B |
December 31, 2020 | 3.522B |
September 30, 2020 | 2.829B |
June 30, 2020 | 2.739B |
March 31, 2020 | 2.806B |
December 31, 2019 | 3.082B |
September 30, 2019 | 3.287B |
June 30, 2019 | 3.024B |
March 31, 2019 | 2.592B |
December 31, 2018 | 3.423B |
September 30, 2018 | 2.47B |
June 30, 2018 | 2.635B |
March 31, 2018 | 2.538B |
Date | Value |
---|---|
December 31, 2017 | 3.163B |
September 30, 2017 | 2.573B |
June 30, 2017 | 2.43B |
March 31, 2017 | 2.377B |
December 31, 2016 | 1.469B |
September 30, 2016 | 2.479B |
June 30, 2016 | 3.143B |
March 31, 2016 | 2.648B |
December 31, 2015 | 2.832B |
September 30, 2015 | 2.758B |
June 30, 2015 | 3.05B |
March 31, 2015 | 2.876B |
December 31, 2014 | 4.172B |
September 30, 2014 | 3.219B |
June 30, 2014 | 3.135B |
March 31, 2014 | 2.798B |
December 31, 2013 | 4.714B |
September 30, 2013 | 2.584B |
June 30, 2013 | 2.619B |
March 31, 2013 | 2.595B |
December 31, 2012 | 2.748B |
September 30, 2012 | 2.449B |
June 30, 2012 | 2.425B |
March 31, 2012 | 2.537B |
December 31, 2011 | 3.226B |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.739B
Minimum
Jun 2020
5.151B
Maximum
Dec 2021
3.886B
Average
3.894B
Median
SG&A Expense (Quarterly) Benchmarks
GSK PLC | 2.647B |
Amgen Inc | 1.808B |
Sanofi SA | 2.830B |
Viking Therapeutics Inc | 9.97M |
Fusion Pharmaceuticals Inc | 7.628M |